Age: 17.0
Sex: F
Vaccine: VARCEL
Symptoms: Injection site erythema, Injection site pain, Injection site pruritus, Injection site swelling, Local reaction
Clinical narrative: chicken pox; This spontaneous report was received from a registered nurse via company representative and referred to a patient with unknown age and gender. The patient's medical history, concurrent conditions were not provided. Concomitant therapies were not reported. Drug reactions/allergies were not provided.  On an unknown date, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) injection, 0.5ml/ series, administered for prophylaxis (strength, lot #, expiry date, and route of administration were not provided).  On an unknown date, the patient developed chicken pox days after vaccination with varicella virus vaccine live (oka/merck) (VARIVAX) (Varicella). It was reported that this was a recent event but was unable to confirm a date of occurrence.  The patient had sought medical attention, but it was unknown whether the patient received treatment. At the time of reporting, the outcome of the event chicken pox was unknown.   The causal relationship between the event and varicella virus vaccine live (oka/merck) (VARIVAX) was not provided.  Follow up information has been received from a registered nurse on 17-APR-2024 referring to a 17-year-old female patient (previously lack of patient's identifiers).   The pre-existing condition included autoimmune disorder. The patient is being seen by immunologist for complaint of (c/o) of immune disorder (no diagnosed yet). The first vaccine (unspecified, no further information) ever given to the patient was on an unspecified date in May 2021. It was informed that no vaccines within 4 weeks prior to the vaccination date (Last set on 02-DEC-2022, unspecified, no further information). Illness at time of vaccination reported as none.  The patient was seen at the clinic for catch up for "17's".  On 11-JAN-2024, the patient was vaccinated with the first dose of varicella virus vaccine live (oka/merck) (VARIVAX) Subcutaneous Injection, Lot # W031812, expiration date: 05-OCT-2024, administered subcutaneous in the left arm. On 24-JAN-2024, the patient returned to the clinic for local site reaction, and she was seen by register nurse. The patient c/o slight itchy, arm achiness, "j-lecm", red, raised area noted; no lesions or blisters; no large lump under skin. On 13-MAR-2024, the patient went to clinic again for other vaccines and the patient's parent stated following previous appointment, the patient ended up setting a mild case of chicken pox (previous reported). This vaccine was used according to the instruction leaflet. Operator of device was reported as health professional (Register nurse) and trained. The adverse event of chicken pox (mild) had not been reported previously. The patient was vaccinated at public health clinical/hospital purchased with private funds. There was not a temperature excursion reported. It was informed that the patient's brother was vaccinated with Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) ant the patient's mother stated that other sibling had "ix" (adverse event and onset age reported as unknown; no further information was provided). The Register nurse reported that the chicken pox was not verified, and it was the patient's mother who reported the chicken pox after a month of the occurrence, and it was requesting more information regarding the PCR testing (also reported as PCR testing of her varicella patient). However, the reported shared that she would not be able to follow the process and was unable to obtain a sample. No other information available. No product quality complaint.  Additional information is not expected.